The NAEPP-EPR3 asthma guidelines: A practical perspective

Research output: Contribution to journalArticle

Abstract

The latest asthma guidelines are characterized by an increased focus on asthma control and individualized treatment to reduce the patient's impairment and risk of exacerbations. The main components of care include frequent assessment of control and monitoring, patient education, control of environmental triggers, and evaluation of the effectiveness of medications. Failure to treat comorbid conditions, such as rhinosinusitis, and insufficient use of spirometry or peak-flow monitoring are common pitfalls. Inhaled corticosteroids (ICSs) continue to be the mainstay of therapy. Long-acting ß2-agonists are the preferred add-on treatment for patients with persistent asthma who have not adequately responded to an ICS alone. For patients with poorly controlled asthma, close monitoring at 2- to 6-week intervals is recommended. Once control is achieved, follow-up at 1- to 6-month intervals is appropriate.

Original languageEnglish (US)
Pages (from-to)481-487
Number of pages7
JournalJournal of Respiratory Diseases
Volume29
Issue number12
StatePublished - Dec 2008

Fingerprint

Asthma
Guidelines
Adrenal Cortex Hormones
Spirometry
Patient Education
Therapeutics

Keywords

  • Allergy
  • Asthma
  • NAEPP guidelines

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

The NAEPP-EPR3 asthma guidelines : A practical perspective. / Zeki, Amir; Kenyon, Nicholas; Louie, Samuel.

In: Journal of Respiratory Diseases, Vol. 29, No. 12, 12.2008, p. 481-487.

Research output: Contribution to journalArticle

@article{fa75f0cd63b14c0c9f57783c18316e56,
title = "The NAEPP-EPR3 asthma guidelines: A practical perspective",
abstract = "The latest asthma guidelines are characterized by an increased focus on asthma control and individualized treatment to reduce the patient's impairment and risk of exacerbations. The main components of care include frequent assessment of control and monitoring, patient education, control of environmental triggers, and evaluation of the effectiveness of medications. Failure to treat comorbid conditions, such as rhinosinusitis, and insufficient use of spirometry or peak-flow monitoring are common pitfalls. Inhaled corticosteroids (ICSs) continue to be the mainstay of therapy. Long-acting {\ss}2-agonists are the preferred add-on treatment for patients with persistent asthma who have not adequately responded to an ICS alone. For patients with poorly controlled asthma, close monitoring at 2- to 6-week intervals is recommended. Once control is achieved, follow-up at 1- to 6-month intervals is appropriate.",
keywords = "Allergy, Asthma, NAEPP guidelines",
author = "Amir Zeki and Nicholas Kenyon and Samuel Louie",
year = "2008",
month = "12",
language = "English (US)",
volume = "29",
pages = "481--487",
journal = "Journal of Respiratory Diseases - For Pediatricians",
issn = "0194-259X",
publisher = "Cliggott Publishing Co.",
number = "12",

}

TY - JOUR

T1 - The NAEPP-EPR3 asthma guidelines

T2 - A practical perspective

AU - Zeki, Amir

AU - Kenyon, Nicholas

AU - Louie, Samuel

PY - 2008/12

Y1 - 2008/12

N2 - The latest asthma guidelines are characterized by an increased focus on asthma control and individualized treatment to reduce the patient's impairment and risk of exacerbations. The main components of care include frequent assessment of control and monitoring, patient education, control of environmental triggers, and evaluation of the effectiveness of medications. Failure to treat comorbid conditions, such as rhinosinusitis, and insufficient use of spirometry or peak-flow monitoring are common pitfalls. Inhaled corticosteroids (ICSs) continue to be the mainstay of therapy. Long-acting ß2-agonists are the preferred add-on treatment for patients with persistent asthma who have not adequately responded to an ICS alone. For patients with poorly controlled asthma, close monitoring at 2- to 6-week intervals is recommended. Once control is achieved, follow-up at 1- to 6-month intervals is appropriate.

AB - The latest asthma guidelines are characterized by an increased focus on asthma control and individualized treatment to reduce the patient's impairment and risk of exacerbations. The main components of care include frequent assessment of control and monitoring, patient education, control of environmental triggers, and evaluation of the effectiveness of medications. Failure to treat comorbid conditions, such as rhinosinusitis, and insufficient use of spirometry or peak-flow monitoring are common pitfalls. Inhaled corticosteroids (ICSs) continue to be the mainstay of therapy. Long-acting ß2-agonists are the preferred add-on treatment for patients with persistent asthma who have not adequately responded to an ICS alone. For patients with poorly controlled asthma, close monitoring at 2- to 6-week intervals is recommended. Once control is achieved, follow-up at 1- to 6-month intervals is appropriate.

KW - Allergy

KW - Asthma

KW - NAEPP guidelines

UR - http://www.scopus.com/inward/record.url?scp=76649106742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76649106742&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:76649106742

VL - 29

SP - 481

EP - 487

JO - Journal of Respiratory Diseases - For Pediatricians

JF - Journal of Respiratory Diseases - For Pediatricians

SN - 0194-259X

IS - 12

ER -